VivoSeq
Musculoskeletal

Back Pain

78

Pipeline Programs↗

8

Active Trials↗

42

Companies Involved↗

Back pain is a moderately active landscape with 78 programs across 42 companies. The most active players are Validus Pharmaceuticals, Fresenius Kabi Oncology Ltd., Vitae Pharmaceuticals Inc., an Allergan affiliate. 28 therapies are approved with 17 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

15/100

Mech. Concentration

24/100

Completion Rate

88/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Validus Pharmaceuticals

1 program

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

Phase 2V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2S

Scilex Pharmaceuticals, Inc.

1 program

Phase 2Daewon Pharmaceutical Co., Ltd. logo

Daewon Pharmaceutical Co., Ltd.

4 programs

Phase 3

Pipeline

Programs by Phase

Preclinical17

Lidocaine Hydrochloride

Citius Pharmaceuticals, Inc.

Naproxen Sodium

Bayer

Ketamine

Aultman Health Foundation

Bupivacaine

Innocoll

Local Anesthetic

Rennes University Hospital

Phase 14

Phenol

Northwestern University

Alocyte Low Dose

Alimorad Farshchian

AMG0103

AnGes, Inc.

TG-C

Kolon TissueGene, Inc.

Phase 212

Desipramine

Validus Pharmaceuticals

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Fluoxetine

Vitae Pharmaceuticals Inc., an Allergan affiliate

Benztropine

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Pamidronate

Hikma Pharmaceuticals LLC

Phase 317

Capsaicin

Averitas Pharma, Inc.

Buprenorphine

Indivior Inc.

Melatonin

Neurim Pharmaceuticals Ltd.

Myonal Tab.

Daewon Pharmaceutical Co., Ltd.

DW-1030

Daewon Pharmaceutical Co., Ltd.

Approved28

Celecoxib

Philadelphia Eye Associates

Ketorolac Tromethamine

Roche

Loratadine

Perrigo Company

Levodopa

Merz Pharmaceuticals GmbH

Escitalopram

AbbVie

Analysis

Trial Status

64

clinical trials

Completed42 · 66%
Unknown status7 · 11%
Withdrawn5 · 8%
Recruiting4 · 6%
Active, not recruiting2 · 3%
Available1 · 2%
Other3 · 5%

Clinical Trials

Trial Activity

64 trials

Effect of Sedation After Ultrasound-Guided Spinal Anesthesia on Back Pain
Recruiting·—·N/A·NCT07198412·180 enrolled
Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain
Recruiting·—·Phase 1·NCT05909709·15 enrolled
Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department
Recruiting·—·Phase 4·NCT06395428·75 enrolled
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
Recruiting·CCreative Medical Technology Holdings Inc·Phase 1/2·NCT06053242·45 enrolled
Melatonin fOr CHronic bAck Pain (The MOCHA Trial)
Active, not recruiting·OOdense University Hospital·Phase 3·NCT06476392·220 enrolled
A Single-Center, Prospective Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain
Active, not recruiting·NNevro Corp·Approved·NCT06897280·25 enrolled
Study to Determine the Safety and Tolerability of TG-C in Subjects with Back Pain Due to Degenerative Disc Disease
Not yet recruiting·KKolon TissueGene, Inc.·Phase 1·NCT06144970·24 enrolled
Randomized Trial Comparing Parallel Versus Perpendicular Technique for Lumbar Medial Branch Radiofrequency Neurotomy
Enrolling by invitation·VVanderbilt University Medical Center·Preclinical·NCT03912519·132 enrolled
Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial
Completed·NNorthwestern University·Phase 4·NCT02013427·82 enrolled
Effect of Antidepressants on Back Pain
Completed·US Department of Veterans Affairs·Phase 2·NCT00018200·130 enrolled
Exploratory Efficacy Study of Guaifenesin in Upper Back Pain
Completed·GSK logoGSK·N/A·NCT01562548·78 enrolled
A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients
Completed·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 3·NCT06595004·310 enrolled
Efficacy and Safety of Lymphdiaral Basistropfen (HDC) in the Treatment of Chronic Low-back Pain
Completed·PPascoe Pharmazeutische Praeparate GmbH·Phase 3·NCT01049373·221 enrolled
A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain
Completed·TTargeted Medical Pharma·Phase 4·NCT01490905·127 enrolled
The Back Pain Consortium Research Program Study
Completed·UUniversity of Michigan·Phase 4·NCT04870957·494 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)